US FDA gives NuPathe's migraine patch 2nd look; verdict set for January
04:20 EDT 1 Aug 2012 | SCRIP
The US FDA has accepted for review NuPathe's resubmitted new drug application for its transdermal sumatriptan migraine patch NP101, giving the firm's shares a 3.6% boost on 31 July, before closing at $3.91, or a gain of 4 cents. The FDA.....
Original Article: US FDA gives NuPathe's migraine patch 2nd look; verdict set for January
More From BioPortfolio on "US FDA gives NuPathe's migraine patch 2nd look; verdict set for January"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
